Valuation: Harrow, Inc.

Market Cap 1.1B 988M 912M 827M 1.54B 105B 1.56B 10.91B 4.35B 54.9B 4.13B 4.05B 174B P/E 2026 *
-274x
P/E 2027 * 13.1x
Enterprise Value 1.1B 988M 912M 827M 1.54B 105B 1.56B 10.91B 4.35B 54.9B 4.13B 4.05B 174B EV / Sales 2026 *
3.15x
EV / Sales 2027 * 2.05x
Free-Float
84.62%
Yield 2026 *
-
Yield 2027 * -
1 day+1.10%
1 week+4.70%
Current month-4.58%
1 month-11.13%
3 months-21.54%
6 months-29.03%
Current year-40.02%
1 week 27.14
Extreme 27.14
29.74
1 month 26.96
Extreme 26.96
31.86
Current year 26.96
Extreme 26.96
54.85
1 year 26.96
Extreme 26.96
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 16/12/2011
President 43 20/08/2025
Compliance Officer - 30/09/2023
Director TitleAgeSince
Chairman 53 18/08/2021
Director/Board Member 57 30/03/2022
Director/Board Member 71 25/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/26 Exercice

Chief Technology Officer

33,750 0.0905%
18/05/26 Buy

Director

1,000 0.0027%
18/05/26 Buy

Director

1,000 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%+4.70%-23.14%+114.37% 1.09B
+0.50%+0.36%+55.89%+129.96% 1,143B
+0.86%+4.50%+42.43%+86.15% 647B
-0.14%-1.07%+25.42%+105.85% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-4.97%+60.15%+37.06% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+2.94%+55.18%+72.74% 242B
+0.08%+1.72%+32.15%+107.78% 197B
Average +0.40%+1.12%+32.42%+80.20% 402.86B
Weighted average by Cap. +0.46%+0.71%+42.61%+89.02%

Financials

2026 *2027 *
Net sales 350M 314M 290M 263M 490M 33.34B 497M 3.47B 1.38B 17.45B 1.31B 1.29B 55.25B 536M 481M 444M 403M 750M 51.06B 761M 5.31B 2.12B 26.73B 2.01B 1.97B 84.63B
Net income -3.92M -3.52M -3.25M -2.94M -5.49M -373M -5.56M -38.83M -15.47M -195M -14.71M -14.4M -619M 89.19M 79.96M 73.84M 66.94M 125M 8.49B 127M 883M 352M 4.44B 335M 328M 14.07B
Net Debt - -
Projected Income Statement - Annual - Harrow, Inc.
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
28/10/26 US$29.39 +1.10% 326,165
27/10/26 US$29.07 +0.41% 635,445
26/10/26 US$28.95 +1.79% 499,149
23/10/26 US$28.44 +1.03% 854,706
22/10/26 US$28.15 -0.32% 440,124
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Harrow, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
29.39USD
Average target price
63.00USD
Spread / Average Target
+114.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Harrow, Inc.
  1. Stock Market
  2. Stocks
  3. HROW Stock